IX Biopharma LTD.
Singapore
- UEI
- UJ73DZNC8HW4
- CAGE
- Q4132
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 20 Collyer Quay, Level 12, Singapore 049319
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $7,127,731 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of the Army | $7,127,731 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Analgesic ketamine product development | Defense Health Agency | $7,127,731 |
Quick answers
Is IX Biopharma LTD. registered in SAM.gov?
Yes. IX Biopharma LTD.'s SAM.gov registration is active through February 23, 2027.
How much has IX Biopharma LTD. received in federal contracts?
Federal contracts obligated $7,127,731 to IX Biopharma LTD. in fiscal years 2023 through 2027.
What is IX Biopharma LTD.'s most recent federal award?
IX Biopharma LTD.'s most recent federal contract award is Analgesic ketamine product development (HT9427269E001), from Defense Health Agency, on February 9, 2026.
On GovTribe
See IX Biopharma LTD.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors